RT Journal Article SR Electronic T1 Novel biomarkers for glycaemic deterioration in type 2 diabetes: an IMI RHAPSODY study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.22.21255625 DO 10.1101/2021.04.22.21255625 A1 Roderick C Slieker A1 Louise A Donnelly A1 Livia Lopez-Noriega A1 Hermine Muniangi-Muhitu A1 Elina Akalestou A1 Mahsa Sheikh A1 Eleni Georgiadou A1 Giuseppe N. Giordano A1 Mikael Åkerlund A1 Emma Ahlqvist A1 Ashfaq Ali A1 Marko Barovic A1 Gerard A Bouland A1 Frédéric Burdet A1 Mickaël Canouil A1 Iulian Dragan A1 Petra JM Elders A1 Celine Fernandez A1 Andreas Festa A1 Hugo Fitipaldi A1 Phillippe Froguel A1 Valborg Gudmundsdottir A1 Vilmundur Gudnason A1 Mathias J. Gerl A1 Amber A van der Heijden A1 Lori L Jennings A1 Michael K. Hansen A1 Min Kim A1 Isabelle Leclerc A1 Christian Klose A1 Dmitry Kuznetsov A1 Dina Mansour Aly A1 Florence Mehl A1 Diana Marek A1 Olle Melander A1 Anne Niknejad A1 Filip Ottosson A1 Imre Pavo A1 Alexander Efanov A1 Kevin Duffin A1 Timothy J. Pullen A1 Kai Simons A1 Michele Solimena A1 Tommi Suvitaival A1 Asger Wretlind A1 Peter Rossing A1 Valeriya Lyssenko A1 Cristina Legido Quigley A1 Leif Groop A1 Bernard Thorens A1 Paul W Franks A1 Mark Ibberson A1 Joline WJ Beulens A1 Leen M ’t Hart A1 Ewan R Pearson A1 Guy A Rutter YR 2021 UL http://medrxiv.org/content/early/2021/04/24/2021.04.22.21255625.abstract AB We have deployed a multi-omics approach in large cohorts of patients with existing type 2 diabetes to identify biomarkers for disease progression across three molecular classes, metabolites, lipids and proteins. A Cox regression analysis for association with time to insulin requirement in 2,973 patients in the DCS, ANDIS and GoDARTS cohorts identified homocitrulline, isoleucine and 2-aminoadipic acid, as well as the bile acids glycocholic and taurocholic acids, as predictive of more rapid deterioration. Increased levels of eight triacylglycerol species, and lowered levels of the sphingomyelin SM 42:2;2 were also predictive of disease progression. Of ∼1,300 proteins examined in two cohorts, levels of GDF-15/MIC1, IL-18RA, CRELD1, NogoR, FAS, and ENPP7 were associated with faster progression, whilst SMAC/DIABLO, COTL1, SPOCK1 and HEMK2 predicted lower progression rates. Strikingly, identified proteins and lipids were also associated with diabetes incidence and prevalence in external replication cohorts. Implicating roles in disease compensation, NogoR/RTN4R improved glucose tolerance in high fat-fed mice and tended to improved insulin signalling in liver cells whilst IL-18R antagonised inflammatory IL-18 signalling towards nuclear factor kappa-B in vitro. Conversely, high NogoR levels led to islet cell apoptosis. This comprehensive, multi-disciplinary approach thus identifies novel biomarkers with potential prognostic utility, provides evidence for new disease mechanisms, and identifies potential therapeutic avenues to slow diabetes progression.Competing Interest StatementKS is CEO of Lipotype GmbH. KS and CK are shareholders of Lipotype GmbH. MJG is employee of Lipotype GmbH. GAR has received grant funding and consultancy fees from Sun Pharmaceuticals and Les Laboratoires Servier. MKH is an employee of Janssen Research & Development, LLC. AF and IP are employees of Eli Lilly Regional Operations GmbH. The AGES-Reykjavik proteomics study was supported by the Novartis Institute for Biomedical Research, and protein measurements for the AGES-Reykjavik cohort were performed at SomaLogic. L.L.J. is an employee and stockholder of Novartis. PR (Peter Rossing) has received honoraria to Steno Diabetes Center Copenhagen for consultancy and teaching from Astellas, Astra Zeneca, Boehringer Ingelheim, Bayer, Novo Nordisk, Sanofi, Gilead and Vifor and research grants from Novo Nordisk and Astra Zeneca. Clinical TrialN/AFunding StatementERP holds a Wellcome Trust New Investigator Award (102820/Z/13/Z). GAR was supported by a Wellcome Trust Investigator Award (212625/Z/18/Z) MRC Programme grants (MR/R022259/1 MR/J0003042/1 MR/L020149/1) an Experimental Challenge Grant (DIVA, MR/L02036X/1) a Diabetes UK Project grant (BDA16/0005485). This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115881 (RHAPSODY). This Joint Undertaking receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education Research and Innovation (SERI) under contract no. 16.0097. VaG is supported by the Icelandic Research Fund (grant no. 184845-051). The Hoorn DCS cohort was supported by grants from the Netherlands Organisation for Health Research and Development (113102006 459001015)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All in vivo procedures were approved by the UK Home Office, according to the Animals (Scientific Procedures) Act 1986 with local ethical committee (Imperial AWERB) approval under personal project license (PPL) number PA03F7F07 to I.L. The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) was approved by the Tayside Medical Ethics Committee and all individuals provided informed consent. In the All New Diabetics in Scania (ANDIS) cohort, people with incident diabetes within Scania County, Sweden were recruited from January 2008 until November 2016 and all participants gave written informed consent. Regional ethics review committee in Lund approved the study. The Hoorn Diabetes Care System (DCS) cohort is a prospective cohort with currently over 14,000 individuals with routine care data. The Ethical Review Committee of the VU University Medical Center, Amsterdam approved the study. In 2008-2014, additional blood sampling was done in 5,500 participants, who provided written informed consent. These samples were used for this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics of lipidomic, proteomic and metabolomic data will be available from an interactive Shiny dashboard available upon publication.